Anifrolumab Clinical Trials
10 recruitingDrug
Phase 33Phase 41Phase 21
Showing 1–10 of 10 trials
Recruiting
Phase 3
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
AstraZeneca245 enrolled79 locationsNCT07430306
Recruiting
Phase 2
Anifrolumab in Adults With Primary Antiphospholipid Syndrome (AnifAPS Trial)
Antiphospholipid Syndrome (APS)
National and Kapodistrian University of Athens20 enrolled1 locationNCT07584083
Recruiting
Phase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Systemic Lupus Erythematosus
AstraZeneca100 enrolled99 locationsNCT05835310
Recruiting
Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
Systemic Lupus Erythematosus
AstraZeneca442 enrolled1 locationNCT06659029
Recruiting
The Anifrolumab PRIM Program
Systemic Lupus Erythematosus
AstraZeneca240 enrolled1 locationNCT06795893
Recruiting
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
Lupus Erythematosus, Systemic
AstraZeneca218 enrolled19 locationsNCT07330245
Recruiting
Anifrolumab Malignancy and Serious Infections Study
Systemic Lupus Erythematosus
AstraZeneca3,195 enrolled4 locationsNCT07000110
Recruiting
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
AstraZeneca100 enrolled11 locationsNCT06673043
Recruiting
Phase 4
Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users
Systemic Lupus Erythematosus
AstraZeneca16 enrolled1 locationNCT06594068
Recruiting
Phase 3
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
Cutaneous Lupus Erythematosus
AstraZeneca302 enrolled272 locationsNCT06015737